EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Ginsenoside Rg1 Ameliorates Pulmonary Hypertension by Inhibiting cGAS/STING Mediated Cell Senescence

Rongzhen Ding iD, Haiping Xie, Yu Zhang, Li Qin, Guoran Peng iD, Jian Yi, Junlan Tan, Xianya Cao, Runxiu Zheng, Aiguo Dai

Drug Design, Development and Therapy · 2025-07 · Volume 19 · 6487-6504

DOI: 10.2147/dddt.s527938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-07. Verfasst von Rongzhen Ding und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410021, People's Republic of China. Hauptthemen laut MEDLINE: Ginsenosides, Hypertension, Pulmonary, Cellular Senescence, Nucleotidyltransferases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary hypertension (PH) is a fatal pulmonary vascular disease that currently lacks effective treatment methods. Ginsenoside Rg1 has positive effects on improving PH, but its specific mechanism remains unclear.

Purpose

This study was designed to investigate the molecular mechanisms of ginsenoside Rg1 in improving PH.

Methods

The therapeutic efficacy of ginsenoside Rg1 in PH rat model was assessed using cardiopulmonary hemodynamic measurements and histopathological staining. Network pharmacology analysis was used to predict potential targets, and the expression of cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway proteins was evaluated by immunofluorescence staining. Senescence marker gene transcription and protein levels were assessed by RT-PCR and immunohistochemistry, respectively. Finally, ELISA was employed to quantify senescence-associated secreted proteins (SASP).

Results

Our results demonstrate that ginsenoside Rg1 significantly reduces right ventricular systolic pressure (RVSP). Ultrasound findings indicate that ginsenoside Rg1 increases the pulmonary artery acceleration time to pulmonary ejection time ratio (PAT/PET) and tricuspid annular plane systolic excursion (TAPSE), while reducing the right ventricular anterior wall thickness (RVAWT). Histological examination (HE) suggests that ginsenoside Rg1 significantly diminishes pulmonary vascular remodeling. Furthermore, ginsenoside Rg1 markedly decreases the mRNA and protein expression of the aging markers p21 and p16, as well as significantly reduces the NF-kB, IL-6, and IL-8.

Conclusion

This study presents compelling evidence that ginsenoside Rg1 may enhance pulmonary vascular remodeling in PH by inhibiting cell senescence via the cGAS/STING signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinsenosidesHypertension, PulmonaryCellular SenescenceNucleotidyltransferasesMembrane ProteinsAnimalsRatsMaleRats, Sprague-DawleyDisease Models, Animal

Stichwörter der Autor:innen

cGAS/STING signaling pathwaycell senescenceginsenoside Rg1pulmonary hypertensionpulmonary vascular remodeling

Substanzen

Ginsenosidesginsenoside Rg1NucleotidyltransferasesMembrane Proteins

Autor:innen und Institutionen

  • Department of Health Management, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410021, People's Republic of China.
  • Department of Respiratory Diseases, Medical School, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.
  • Hunan Provincial Key Laboratory of Vascular Biology and Translational Medicine, Changsha, Hunan, 410208, People's Republic of China.
  • Department of Urology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410021, People's Republic of China.
  • Laboratory of Stem Cell Regulation with Chinese Medicine and Its Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.
  • Department of Gerontology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410021, People's Republic of China.

ORCID-Profile: Rongzhen Ding, Guoran Peng

Zitieren

APA

Ding, R., Xie, H., Zhang, Y., Qin, L., Peng, G., Yi, J., Tan, J., Cao, X., Zheng, R., & Dai, A. (2025). Ginsenoside Rg1 Ameliorates Pulmonary Hypertension by Inhibiting cGAS/STING Mediated Cell Senescence. Drug Design, Development and Therapy, Volume 19, 6487-6504. https://doi.org/10.2147/dddt.s527938

Vancouver

Ding R, Xie H, Zhang Y, Qin L, Peng G, Yi J, et al. Ginsenoside Rg1 Ameliorates Pulmonary Hypertension by Inhibiting cGAS/STING Mediated Cell Senescence. Drug Design, Development and Therapy. 2025;Volume 19:6487-6504. doi:10.2147/dddt.s527938

BibTeX
@article{Ding2025,
  author = {Ding, Rongzhen and Xie, Haiping and Zhang, Yu and Qin, Li and Peng, Guoran and Yi, Jian and Tan, Junlan and Cao, Xianya and Zheng, Runxiu and Dai, Aiguo},
  title = {Ginsenoside Rg1 Ameliorates Pulmonary Hypertension by Inhibiting cGAS/STING Mediated Cell Senescence},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {6487--6504},
  doi = {10.2147/dddt.s527938}
}
Kostenlos starten →